Dupixent® (dupilumab) sbla accepted for fda priority review for treatment of adolescents with chronic rhinosinusitis with nasal polyposis (crswnp)

If approved, dupixent would be the first treatment in the u.s. indicated for adolescents aged 12-17 years with inadequately controlled crswnp, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell
REGN Ratings Summary
REGN Quant Ranking